Bitolterol mesylate (Tornalate) is a short-acting
β2 adrenergic receptor agonist used for the relief of
bronchospasm in conditions such as
asthma[1][2] and
COPD.[3][4][5] In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi worsen this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.
Bitolterol is a
prodrug of
colterol.[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.[8]
The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.[9]
^"Early Career Awards for 1978 (John Robert Anderson, Philip M. Groves, Gary E. Schwartz)". The American Psychologist. 34 (1): 69–79. January 1979.
doi:
10.1037/h0078247.
PMID396832.
Bitolterol mesylate (Tornalate) is a short-acting
β2 adrenergic receptor agonist used for the relief of
bronchospasm in conditions such as
asthma[1][2] and
COPD.[3][4][5] In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi worsen this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.
Bitolterol is a
prodrug of
colterol.[6][7] It has a rapid onset of action (2–5 minutes) and may last up to 6–8 hours.[8]
The drug, alone or in co-administration with theophylline, doesn't show cardiotoxic effect.[9]
^"Early Career Awards for 1978 (John Robert Anderson, Philip M. Groves, Gary E. Schwartz)". The American Psychologist. 34 (1): 69–79. January 1979.
doi:
10.1037/h0078247.
PMID396832.